BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Beacon Medical Professionals - ECPv6.6.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.beaconhealthsystem.org/medical-professionals
X-WR-CALDESC:Events for Beacon Medical Professionals
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Indiana/Indianapolis
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231018
DTEND;VALUE=DATE:20231019
DTSTAMP:20260408T052912
CREATED:20230719T173718Z
LAST-MODIFIED:20231018T174253Z
UID:10000379-1697587200-1697673599@www.beaconhealthsystem.org
SUMMARY:Advancing the Treatment of Patients With Myelofibrosis
DESCRIPTION:Click HERE to Access Webinar OnDemand Recording  \nClick HERE to Access CME Evaluation  \nAdvancing the Treatment of Patients With Myelofibrosis \nPresented By: Aaron T. Gerds\, MD\, MS – Associate Professor of Medicine and Deputy Director for Clinical Research\, Cleveland Clinic Taussig Cancer Institute \nLearning Objectives: \n• Review the disease burden experienced by patients with myelofibrosis.\n• Initiate treatment based on patient prognosis and characteristics.\n• Implement strategies\, including modifying therapy\, to overcome treatment barriers.\n• Describe the safety and efficacy of emerging novel therapies for myelofibrosis. \nAaron Gerds\, MD\, MS\, is an associate professor of medicine and deputy director for clinical research at the Cleveland Clinic Taussig Cancer Institute and medical director of the Clinical Research Office for Case Western Reserve University’s Case Comprehensive Cancer Center. Dr. Gerds received his medical degree from Loyola University Chicago Stritch School of Medicine where he also completed his residency. He was awarded a fellowship in hematology/oncology by the University of Washington’s Fred Hutchinson Cancer Center in Seattle.\nDr. Gerds’ clinical and research interests focus on optimizing current treatments\, and developing new therapies for patients with myeloproliferative disorders and other myeloid neoplasia. He serves as principal investigator for a number of clinical trials.\nAn active member of the American Society of Hematology\, Dr. Gerds participates in both the organization’s Advocacy Leadership Institute and Clinical Research Training Institute. He also chairs the National Comprehensive Cancer Network’s MPN guidelines panel. Dr. Gerds is the author or coauthor of numerous journal articles and abstracts and serves as editor-in-chief of ASH Clinical News.
URL:https://www.beaconhealthsystem.org/medical-professionals/event/advancing-the-treatment-of-patients-with-myelofibrosis/
LOCATION:Patel Auditorium at Elkhart General Hospital\, 600 East Boulevard\, Elkhart\, IN\, 46514\, United States
CATEGORIES:CME Events,On Demand CME Events
END:VEVENT
END:VCALENDAR